Syndecan-1 serves as a biomarker of glycocalyx degradation (Rehm et al., 2007) and is released into the blood under stressful conditions such as AKI, chronic kidney disease, and cardiovascular disease (Puskarich et al., 2016). Here, SDC1 is linked to cardiovascular disorder.